Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

UNICEF is working to strengthen under-resourced health systems around the world to improve outcomes for children and family ...

Sanofi has struck a deal in the hotly competitive radiopharmaceuticals sector, buying a $300mn stake in a subsidiary of ...

Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...

This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Tirzepatide is seeking label expansions in treating obstructive sleep apnea and in reducing the likelihood of developing type ...

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

There's no playbook for how to be competitive in artificial intelligence (AI) as a big pharma company, but Eli Lilly (NYSE: LLY) is taking a shot at developing one. With the appointment of a new chief ...

Severe malnutrition is treated with ready-to-use therapeutic food, a paste combining peanuts, sugar, milk powder, oil, ...

Unfortunately, many of our elected leaders today undervalue the role of patents to progress the science of drug discovery and ...